Literature DB >> 26921362

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.

Douglas F Easton1, Fabienne Lesueur2, Brennan Decker3, Kyriaki Michailidou4, Jun Li5, Jamie Allen6, Craig Luccarini7, Karen A Pooley6, Mitul Shah7, Manjeet K Bolla6, Qin Wang6, Joe Dennis6, Jamil Ahmad8, Ella R Thompson9, Francesca Damiola10, Maroulio Pertesi8, Catherine Voegele8, Noura Mebirouk2, Nivonirina Robinot8, Geoffroy Durand8, Nathalie Forey8, Robert N Luben11, Shahana Ahmed7, Kristiina Aittomäki12, Hoda Anton-Culver13, Volker Arndt14, Caroline Baynes7, Matthias W Beckman15, Javier Benitez16, David Van Den Berg17, William J Blot18, Natalia V Bogdanova19, Stig E Bojesen20, Hermann Brenner21, Jenny Chang-Claude22, Kee Seng Chia23, Ji-Yeob Choi24, Don M Conroy7, Angela Cox25, Simon S Cross26, Kamila Czene27, Hatef Darabi27, Peter Devilee28, Mikael Eriksson27, Peter A Fasching29, Jonine Figueroa30, Henrik Flyger31, Florentia Fostira32, Montserrat García-Closas33, Graham G Giles34, Gord Glendon35, Anna González-Neira36, Pascal Guénel37, Christopher A Haiman17, Per Hall27, Steven N Hart38, Mikael Hartman39, Maartje J Hooning40, Chia-Ni Hsiung41, Hidemi Ito42, Anna Jakubowska43, Paul A James44, Esther M John45, Nichola Johnson46, Michael Jones47, Maria Kabisch48, Daehee Kang49, Veli-Matti Kosma50, Vessela Kristensen51, Diether Lambrechts52, Na Li53, Annika Lindblom54, Jirong Long55, Artitaya Lophatananon56, Jan Lubinski43, Arto Mannermaa50, Siranoush Manoukian57, Sara Margolin58, Keitaro Matsuo59, Alfons Meindl60, Gillian Mitchell61, Kenneth Muir62, Ines Nevelsteen63, Ans van den Ouweland64, Paolo Peterlongo65, Sze Yee Phuah66, Katri Pylkäs67, Simone M Rowley68, Suleeporn Sangrajrang69, Rita K Schmutzler70, Chen-Yang Shen71, Xiao-Ou Shu72, Melissa C Southey73, Harald Surowy74, Anthony Swerdlow75, Soo H Teo66, Rob A E M Tollenaar76, Ian Tomlinson77, Diana Torres78, Thérèse Truong37, Celine Vachon38, Senno Verhoef79, Michelle Wong-Brown80, Wei Zheng55, Ying Zheng81, Heli Nevanlinna82, Rodney J Scott83, Irene L Andrulis84, Anna H Wu17, John L Hopper85, Fergus J Couch86, Robert Winqvist67, Barbara Burwinkel74, Elinor J Sawyer87, Marjanka K Schmidt79, Anja Rudolph88, Thilo Dörk89, Hiltrud Brauch90, Ute Hamann48, Susan L Neuhausen91, Roger L Milne34, Olivia Fletcher46, Paul D P Pharoah1, Ian G Campbell92, Alison M Dunning7, Florence Le Calvez-Kelm8, David E Goldgar93, Sean V Tavtigian94, Georgia Chenevix-Trench5.   

Abstract

BACKGROUND: BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast cancer risk prediction.
METHODS: We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 controls from three population-based studies as part of the Breast Cancer Family Registry, and 1853 familial cases and 2001 controls from Australia.
RESULTS: The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48 to 1.70, p=0.75).
CONCLUSIONS: These results suggest that truncating variants in BRIP1, and in particular p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations have important implications for the reporting of results from breast cancer screening panels. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Cancer: breast

Mesh:

Substances:

Year:  2016        PMID: 26921362      PMCID: PMC4938802          DOI: 10.1136/jmedgenet-2015-103529

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  42 in total

1.  A linear complexity phasing method for thousands of genomes.

Authors:  Olivier Delaneau; Jonathan Marchini; Jean-François Zagury
Journal:  Nat Methods       Date:  2011-12-04       Impact factor: 28.547

2.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.

Authors:  Rachel Litman; Min Peng; Zhe Jin; Fan Zhang; Junran Zhang; Simon Powell; Paul R Andreassen; Sharon B Cantor
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

3.  Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Authors:  A-Yong Cao; Juan Huang; Zhen Hu; Wen-Feng Li; Zhong-Liang Ma; Li-Li Tang; Bin Zhang; Feng-Xi Su; Jie Zhou; Gen-Hong Di; Kun-Wei Shen; Jiong Wu; Jin-Song Lu; Jian-Min Luo; Wen-Tao Yuan; Zhen-Zhou Shen; Wei Huang; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2008-05-16       Impact factor: 4.872

4.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

5.  Rare mutations in XRCC2 increase the risk of breast cancer.

Authors:  D J Park; F Lesueur; T Nguyen-Dumont; M Pertesi; F Odefrey; F Hammet; S L Neuhausen; E M John; I L Andrulis; M B Terry; M Daly; S Buys; F Le Calvez-Kelm; A Lonie; B J Pope; H Tsimiklis; C Voegele; F M Hilbers; N Hoogerbrugge; A Barroso; A Osorio; G G Giles; P Devilee; J Benitez; J L Hopper; S V Tavtigian; D E Goldgar; M C Southey
Journal:  Am J Hum Genet       Date:  2012-03-29       Impact factor: 11.025

6.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.

Authors:  Sean V Tavtigian; Peter J Oefner; Davit Babikyan; Anne Hartmann; Sue Healey; Florence Le Calvez-Kelm; Fabienne Lesueur; Graham B Byrnes; Shu-Chun Chuang; Nathalie Forey; Corinna Feuchtinger; Lydie Gioia; Janet Hall; Mia Hashibe; Barbara Herte; Sandrine McKay-Chopin; Alun Thomas; Maxime P Vallée; Catherine Voegele; Penelope M Webb; David C Whiteman; Suleeporn Sangrajrang; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2009-09-24       Impact factor: 11.025

7.  Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.

Authors:  Frédéric Guénard; Yvan Labrie; Geneviève Ouellette; Charles Joly Beauparlant; Jacques Simard; Francine Durocher
Journal:  J Hum Genet       Date:  2008-04-15       Impact factor: 3.172

8.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

9.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

Authors:  Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

10.  RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.

Authors:  Florence Le Calvez-Kelm; Javier Oliver; Francesca Damiola; Nathalie Forey; Nivonirina Robinot; Geoffroy Durand; Catherine Voegele; Maxime P Vallée; Graham Byrnes; Breast Cancer Family Registry; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian; Fabienne Lesueur
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more
  45 in total

Review 1.  Update on Genetic Testing in Gynecologic Cancer.

Authors:  Susan M Domchek; Mark E Robson
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

2.  Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.

Authors:  Lisa Golmard; Laurent Castéra; Sophie Krieger; Virginie Moncoutier; Khadija Abidallah; Henrique Tenreiro; Anthony Laugé; Julien Tarabeux; Gael A Millot; André Nicolas; Marick Laé; Caroline Abadie; Pascaline Berthet; Florence Polycarpe; Thierry Frébourg; Camille Elan; Antoine de Pauw; Marion Gauthier-Villars; Bruno Buecher; Marc-Henri Stern; Dominique Stoppa-Lyonnet; Dominique Vaur; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2017-11-08       Impact factor: 4.246

3.  Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.

Authors:  Hsiao-Mei Lu; Shuwei Li; Mary Helen Black; Shela Lee; Robert Hoiness; Sitao Wu; Wenbo Mu; Robert Huether; Jefferey Chen; Srijani Sridhar; Yuan Tian; Rachel McFarland; Jill Dolinsky; Brigette Tippin Davis; Sharon Mexal; Charles Dunlop; Aaron Elliott
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

Review 4.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

Review 5.  Counselling framework for moderate-penetrance cancer-susceptibility mutations.

Authors:  Nadine Tung; Susan M Domchek; Zsofia Stadler; Katherine L Nathanson; Fergus Couch; Judy E Garber; Kenneth Offit; Mark E Robson
Journal:  Nat Rev Clin Oncol       Date:  2016-06-14       Impact factor: 66.675

6.  The use of panel testing in familial breast and ovarian cancer.

Authors:  Matina Prapa; Joyce Solomons; Marc Tischkowitz
Journal:  Clin Med (Lond)       Date:  2017-12       Impact factor: 2.659

7.  Expanding the spectrum of germline variants in cancer.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Sandeep Kumar Parvathareddy; Ismail A Al-Badawi; Nasser Al-Sanea; Luai H Ashari; Alaa Abduljabbar; Samar Alhomoud; Saif S Al-Sobhi; Asma Tulbah; Dahish Ajarim; Khalid Alzoman; Muna Aljuboury; Hussam Bin Yousef; Mohammed Al-Dawish; Fouad Al-Dayel; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Hum Genet       Date:  2017-10-03       Impact factor: 4.132

8.  Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.

Authors:  Koji Shindo; Jun Yu; Masaya Suenaga; Shahriar Fesharakizadeh; Christy Cho; Anne Macgregor-Das; Abdulrehman Siddiqui; P Dane Witmer; Koji Tamura; Tae Jun Song; Jose Alejandro Navarro Almario; Aaron Brant; Michael Borges; Madeline Ford; Thomas Barkley; Jin He; Matthew J Weiss; Christopher L Wolfgang; Nicholas J Roberts; Ralph H Hruban; Alison P Klein; Michael Goggins
Journal:  J Clin Oncol       Date:  2017-08-02       Impact factor: 44.544

9.  Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.

Authors:  Sandra Bonache; Irene Esteban; Alejandro Moles-Fernández; Anna Tenés; Laura Duran-Lozano; Gemma Montalban; Vanessa Bach; Estela Carrasco; Neus Gadea; Adrià López-Fernández; Sara Torres-Esquius; Francesco Mancuso; Ginevra Caratú; Ana Vivancos; Noemí Tuset; Judith Balmaña; Sara Gutiérrez-Enríquez; Orland Diez
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-10       Impact factor: 4.553

Review 10.  Hereditary breast and ovarian cancer: new genes in confined pathways.

Authors:  Finn Cilius Nielsen; Thomas van Overeem Hansen; Claus Storgaard Sørensen
Journal:  Nat Rev Cancer       Date:  2016-08-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.